Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Med Trop (Mars) ; 55(4 Suppl): 41-6, 1995.
Article in English | MEDLINE | ID: mdl-8649265

ABSTRACT

Malaria, especially that due to Plasmodium falciparum, is one of the most important parasitic disease in man. It causes more than 400 million cases per year and between 1 to 3 million deaths, mainly among young children and pregnant women in sub-Saharan Africa. The current malaria control strategies using rapid diagnosis and treatment as well as methods to reduce the man-vector contact have had limited success. In Kilombero district (Southern Tanzania), malaria transmission is perennial (parasite prevalence > or = 80% all year) and intense (approximatively 300 infectious bites per year). At the household level, each under-5 child suffers on average 3 clinical fever episodes per year. Minimum estimated community rates for serious malaria (cerebral malaria or malaria and anaemia) affect approximatively 5% of all children. Under conditions of a field experiment, the annual incidence of a febrile illness (axillary temperature > or = 37.5 degrees C) reported to the curative primary health services in each child was 0.86 of which 0,35 can be attributed to Plasmodium falciparum malaria. The best estimate of the SPf66 vaccine protective efficacy in the Kilombero was 31% (95% CI : 0.52).


Subject(s)
Malaria Vaccines/administration & dosage , Malaria, Falciparum/prevention & control , Protozoan Proteins/administration & dosage , Recombinant Proteins , Child, Preschool , Female , Humans , Incidence , Infant , Infant, Newborn , Malaria Vaccines/immunology , Malaria, Falciparum/epidemiology , Malaria, Falciparum/parasitology , Male , Population Surveillance , Prevalence , Protozoan Proteins/immunology , Rural Health , Tanzania/epidemiology
2.
Lancet ; 344(8931): 1175-81, 1994 Oct 29.
Article in English | MEDLINE | ID: mdl-7934537

ABSTRACT

Effective, safe antimalarial vaccines have proved elusive. The synthetic polypeptide SPf66 vaccine is based on preerythrocytic and asexual blood-stage proteins of Plasmodium falciparum. We report here a randomised double-blind placebo-controlled trial of the efficacy of the SPf66 vaccine against clinical P falciparum malaria in idete, southern Tanzania, an area of intense perennial malaria transmission. 586 children aged 1-5 years received three doses of vaccine (n = 274) or placebo (n = 312). The incidence and density of parasitaemia were assessed through repeated cross-sectional surveys on subgroups of children. Morbidity was monitored over a 1 year period through passive case detection in all children plus active case detection in a subgroup of 191. An episode of clinical malaria was defined as measured fever (> or = 37.5 degrees C) and parasite density > 20,000/microL. No severe side-effects were seen and the frequency of mild side-effects after the third dose was less than 6%. The vaccine was highly immunogenic and after three doses all vaccine recipients had detectable anti-SPf66 antibodies: the geometric mean index of response was 8.3 in the vaccine group and 0.7 in the placebo group. The incidence of parasitaemia was similar in both groups. 123 children had at least one episode of clinical malaria during the follow-up period after the third dose and annual incidence rates were 0.25 in the vaccine group and 0.35 in the placebo group. Estimated vaccine efficacy was 31% (95% confidence interval 0-52%; p = 0.046). After the third dose there were 6 deaths among the study cohort (1 vaccine, 5 placebo). This study confirms that SPf66 is safe, immunogenic and reduces the risk of clinical malaria among children exposed to intense P falciparum transmission.


Subject(s)
Malaria Vaccines , Malaria, Falciparum/prevention & control , Protozoan Proteins , Recombinant Proteins , Vaccination , Child, Preschool , Cross-Sectional Studies , Double-Blind Method , Follow-Up Studies , Humans , Immunization Schedule , Infant , Informed Consent , Malaria Vaccines/administration & dosage , Malaria, Falciparum/immunology , Malaria, Falciparum/parasitology , Protozoan Proteins/administration & dosage , Tanzania/epidemiology
3.
Acta Trop ; 57(4): 289-300, 1994 Sep.
Article in English | MEDLINE | ID: mdl-7810385

ABSTRACT

Malaria remains a major public health challenge in sub-Saharan Africa, yet our knowledge of the epidemiology of malaria in terms of patterns of mortality and morbidity is limited. We have examined the presentation of severe, potentially life-threatening malaria to district hospitals in two very different transmission settings: Kilifi, Kenya with low seasonal transmission and Ifakara, Tanzania with high seasonal transmission. The minimum annual rates of severe disease in children below five years in both populations were similar (46 per 1000 children in Kilifi and 51 per 1000 children in Ifakara). However, there were important differences in the age and clinical patterns of severe disease; twice as many patients were under one year of age in Ifakara compared with Kilifi and there was a four fold higher rate of cerebral malaria and three fold lower rate of malaria anaemia among malaria patients at Kilifi compared with Ifakara. Reducing malaria transmission in Ifakara by 95%, for example with insecticide-treated bed nets, would result in a transmission setting comparable to that of Kilifi and although this reduction may yield early successes in reducing severe malaria morbidity and mortality in young, immunologically naive children, place these same children at increased risk at older ages of developing severe and potentially different manifestations of malaria infection hence producing no net cohort gain in survivorship from potentially fatal malaria.


Subject(s)
Malaria, Falciparum/epidemiology , Malaria, Falciparum/transmission , Anemia/complications , Anemia/epidemiology , Child , Child, Preschool , Hookworm Infections/complications , Hookworm Infections/epidemiology , Hospitals, Rural , Humans , Infant , Kenya/epidemiology , Malaria, Cerebral/epidemiology , Malaria, Falciparum/mortality , Seasons , Tanzania/epidemiology
4.
Vaccine ; 12(4): 328-36, 1994 Mar.
Article in English | MEDLINE | ID: mdl-8178555

ABSTRACT

As part of the first trial of the SPf66 malaria vaccine in Africa, three randomized double-blind placebo-controlled studies of SPf66 have been conducted in a highly endemic area of Tanzania. The objectives were to confirm that the product is immunogenic and safe in highly exposed individuals. Results from ten male adult expatriates indicated that the product used in Tanzania is at least as immunogenic as that used in Colombia. No major side-effects were observed in indigenous SPf66 recipients (18 adults, and 25 children aged 1-4 years). Anti-SPf66 antibody titres in all groups showed clear responses to three doses of the vaccine.


Subject(s)
Malaria Vaccines/adverse effects , Malaria Vaccines/immunology , Plasmodium falciparum/immunology , Protozoan Proteins/adverse effects , Protozoan Proteins/immunology , Recombinant Proteins , Adolescent , Adult , Animals , Child, Preschool , Double-Blind Method , Follow-Up Studies , Humans , Infant , Male , Middle Aged , Tanzania , Vaccines, Synthetic/adverse effects , Vaccines, Synthetic/immunology
5.
Vaccine ; 12(2): 181-6, 1994 Feb.
Article in English | MEDLINE | ID: mdl-8147101

ABSTRACT

The development of a safe, affordable and effective malaria vaccine to form part of control schemes in malaria endemic countries is a priority for researchers and public health officials. SPf66 is the first malaria vaccine to have shown partial protection against natural challenge in a phase III trial carried out in a hypoendemic area of Colombia. This paper describes the rationale and design of the first field trial of SPf66 outside South America, and the first to be conducted in an area of high perennial transmission.


Subject(s)
Malaria Vaccines , Malaria, Falciparum/prevention & control , Protozoan Proteins/immunology , Recombinant Proteins , Adult , Animals , Child, Preschool , Ethics, Medical , Humans , Infant , Malaria Vaccines/adverse effects , Malaria Vaccines/immunology , Male , Plasmodium falciparum/immunology , Protozoan Vaccines , Safety , Tanzania , Vaccines, Synthetic/adverse effects , Vaccines, Synthetic/immunology , Vaccines, Synthetic/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...